Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 10/20 | 0.46 |
| ▸ | CA1 | P00915 | 5/20 | 0.37 |
| ▸ | CA9 | Q16790 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA4 | P22748 | 2/20 | 0.30 |
| ▸ | CA5A | P35218 | 2/20 | 0.30 |
| ▸ | CA7 | P43166 | 2/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.30 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.30 |
| ▸ | CA6 | P23280 | 1/20 | 0.30 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2480054 | 0.82 | — | — | |
| SCHEMBL2540229 | 0.82 | — | — | |
| SCHEMBL243965 | 0.82 | — | — | |
| Bicarbonate SCHEMBL7042448 | 0.77 | HCRTR2 (0.36) | CA2CA1 | |
| SCHEMBL28294175 | 0.73 | HCRTR2 (0.37) | CA2 | |
| SCHEMBL22682158 | 0.71 | CA2 (0.30) | CA2 | |
| SCHEMBL3767312 | 0.68 | CA2 (0.42) | CA2CA1CA9CA12CA4 | |
| SCHEMBL1145603 | 0.64 | CA2 (0.58) | CA2CA1CA9CA12CA4 | |
| SCHEMBL5049810 | 0.64 | CA2 (0.42) | CA2CA1CA9 | |
| SCHEMBL16051098 | 0.63 | CA2 (0.71) | CA2CA1CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7842836-B2 | N-aryl-N'alkyl sulfamides as MEK inhibitors | ARDEA BIOSCIENCES (US) | 2010-11-30 | — | — | US | disclosed |
| WO-2007121269-A2 | N-ARYL-N'ALKYL SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES, INC. (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070238710-A1 | N-ARYL-N'ALKYL SULFAMIDES AS MEK INHIBITORS | ARDEA BIOSCIENCES (US) | 2007-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238710-A1 | N-ARYL-N'ALKYL SULFAMIDES AS MEK INHIBITORS | NRAS, BRAF, HRAS | CA2 4804/4885CA1 4884/4885CA9 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.